Current status and challenges of TCR-T cell therapy for AML/MDS.

Authors

Yoshiki Akatsuka

Published in

International journal of hematology. Jun 18, 2026. Epub Jun 18, 2026.

Abstract

Although novel drugs have recently been introduced in the clinic, the survival rates of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are not yet satisfactory; thus, developing novel strategies with different modes of action is urgently needed. Immunotherapy against AML/MDS is less feasible than that for B-cell malignancies because commonly and uniformly expressed cell-surface targets are lacking, and HLA constraints further limit patient eligibility. Careful patient selection based on high and homogeneous target antigen expression in AML/MDS cells may serve as a biomarker. In this review, we first describe T-cell receptor (TCR) T-cell therapy development processes, then review recent clinical trials and future perspectives.

PMID:
42315760
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.